Quantcast
Last updated on April 18, 2014 at 21:21 EDT

Latest Channelopathy Stories

2013-11-27 12:23:47

One Year Anniversary of Canadian Approval for KALYDECO Goes by Without Public Access TORONTO, Nov. 27, 2013 /CNW/ - Canadians with cystic Fibrosis (CF) have been living with unequal access to treatment for a full year now as KALYDECO a life-saving treatment for this disease celebrates its one year anniversary of approval by Health Canada without wide spread public drug plan coverage. Some Canadians have been lucky enough to receive this medication through their private...

2013-11-12 09:10:29

American Heart Association Rapid Access Journal Report A promising technology may enable doctors to diagnose and possibly treat in utero a common cause of stillbirth and sudden death in infants, according to research published in the American Heart Association journal Circulation. The study is the first to document the electrophysiological characteristics of fetal long QT syndrome and to evaluate the diagnostic accuracy of the magnetic EKG, or magnetocardiogram, in a sizable population...

2013-11-08 23:04:48

Inter-professional Care provided to a 9 year old girl with genetic mutation for Long QT Syndrome. New York (PRWEB) November 08, 2013 As a researcher at Pace University in New York, Esma Paljevic, EdD, RN, CPNP, was astonished to find out that according to the American Heart Association there were 4000 deaths per year in individuals under the age of 35 due to undiagnosed disturbances of heart rhythm, such as long QT Syndrome (2009). Paljevic is an assistant professor of nursing at Pace...

2013-10-22 23:27:35

LizArt Gallery, a website featuring photographs and gifts from artist Elizabeth Sohnle, is pleased to announce a new campaign aimed to raise awareness and funds for cystic fibrosis. (PRWEB) October 22, 2013 Elizabeth Sohnle Fine Art Photographer is pleased to announce a new campaign aimed to increase public awareness and raise money for the Cystic Fibrosis Foundation, both locally and nationally. Her website http://www.lizartgallery.com features acclaimed photographs and gifts from artist...

2013-10-16 23:26:25

Announcement comes on the first day of the North American Cystic Fibrosis Conference, where the latest data on N8's patented biopharmaceutical will be presented. Columbus, OH (PRWEB) October 16, 2013 N8 Medical, Inc., a biopharmaceutical company commercializing innovative therapeutics and combination devices to address critical unmet needs in infectious disease and oncology, today announced that Michael Triplett, Ph.D. assumed the role of Chief Executive Officer of N8 Medical on...

2013-10-15 20:47:06

Powerful tool may lead to treatment of RP Research led by physician-scientists at Bascom Palmer Eye Institute of the University of Miami Miller School of Medicine has produced a breakthrough discovery in diagnosing retinitis pigmentosa, a blinding disease that affects about 1 in 4,000 people in the United States. Rong Wen, M.D., Ph.D., and Byron Lam, M.D., professors of ophthalmology at Bascom Palmer, in collaboration with biochemist Ziqiang Guan, Ph.D., a research associate professor...

2013-10-15 08:29:53

BOULDER, Colo., Oct. 15, 2013 /PRNewswire/ -- N30 Pharmaceuticals, Inc. today announced presentations regarding its novel portfolio of compounds for the potential treatment of cystic fibrosis at the 2013 North American Cystic Fibrosis Conference, which will be held October 17-19, 2013 in Salt Lake City, Utah. The presentations include preclinical data on its first-in-class inhibitors of S-nitrosoglutathione reductase (GSNORi) and its novel correctors of CFTR, the dysfunctional protein...

2013-10-10 16:27:01

ATLANTA, Oct. 10, 2013 /PRNewswire/ -- Pharmaceutical discovery and development company Celtaxsys, Inc. today announced it is now enrolling patients for its first trial of CTX-4430 oral treatment for lung disease in Cystic Fibrosis (CF) patients. In this study, the safety and tolerability of CTX-4430 will be assessed at several dose levels when administered orally once-daily for 2 weeks. Additional assessments will include pharmacokinetics and biomarkers, as well as effects on lung...

2013-10-01 23:36:23

Best in Backyards will sponsor its local Boy Scout troop for the upcoming “Wrestle Cure,” a charitable event whose proceeds benefit Cystic Fibrosis. The event will take place on November 8th at 7 p.m. at the old High School in Mahopac N.Y. Mahopac, New York (PRWEB) October 01, 2013 Best in Backyards, New York and Connecticut’s leading provider of swing sets and other recreational backyard amenities, announces its sponsorship of Boy Scout Troop No. 1 for “Wrestle Cure.” The...

2013-09-27 23:25:28

Helping CF Patients Breathe Easier Claremont, CA (PRWEB) September 27, 2013 Synedgen announces the award of a National Heart Lung and Blood Institute (NHLBI) Small Business Innovation Research grant from the NIH to explore the mechanisms of a natural modified biopolymer to both reduce the viscosity of mucus and the cohesion of biofilms, potentially leading to a pulmonary treatment for patients with cystic fibrosis (CF) to enhance airway clearance and augment the activity of standard...


Latest Channelopathy Reference Libraries

Cystic Fibrosis
2013-07-19 15:03:45

Cystic fibrosis, also called mucoviscidosis, is an autosomal recessive genetic disorder of the viscous secretions in the body. In turn, it effects the lungs, pancreas, liver, and intestines, as well as all other exocrine glands in the body. The most common genetic mutation that causes CF is a deletion of three nucleotides that results in a loss of phenylalanine, an amino acid at the 508th position on the protein. It should be noted, however, that there are over a thousand other mutations that...

More Articles (1 articles) »